List view / Grid view



NICE says ‘no’ to alirocumab in draft guidance

8 February 2016 | By

NICE was concerned that alirocumab had not been compared with the combination therapy of ezetimibe plus a statin and that trials of the drug were not able to provide robust information on cardiovascular outcomes...

FDA accepts lixisenatide NDA for review

29 September 2015 | By

The NDA submission for lixisenatide is based on results from the GetGoal clinical programme and includes findings from the recently-completed ELIXA study...

Send this to a friend